On April 20, 2026 Takara Bio USA, Inc., a wholly owned subsidiary of Takara Bio Inc. ("Takara Bio"), reported data from a benchmark study comparing key performance metrics of its Trekker FX technology against conventional spatial methods. This study was conducted using formalin-fixed paraffin-embedded (FFPE) tissue samples from human lung squamous cell carcinoma. This study is the first in a planned series of independent studies to validate the advantages of Trekker FX technology over other existing spatial transcriptomics products. Takara Bio USA will present a poster on the findings at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) conference, taking place this week in San Diego.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"This benchmark study demonstrates that Trekker FX enables higher resolution, easier scalability, and deeper unbiased spatial characterization and insights than other methods," said Andrew Farmer, PhD, CSO of Takara Bio USA. "By combining true single-cell spatial mapping with broad molecular detection, the Trekker approach represents an entirely new class of spatial technology that complements existing single-cell sequencing workflows and expands what researchers can reveal in a cell’s native tissue environment."

In this benchmark study, Trekker FX delivered improved whole-transcriptome detection through its unique donation-based spatial tagging approach, which maintains single-cell NGS sensitivity. This results in Trekker FX being able to identify key subpopulations relevant in tumor biology (i.e., Tregs, plasmacytoid dendritic cells, lymphatic endothelial cells, and others). Trekker FX also identified 3X more statistically significant ligand-receptor interactions to better uncover how cells communicate within the tumor microenvironment.

The benchmark study was conducted by Takara Bio Genome Analysis Center in Japan, leveraging its world-class service capabilities and expertise across various spatial products and solutions. As a global leader in biotech research and development, Takara Bio offers a wide range of services that help scientists around the world push their research to new frontiers with a comprehensive array of technologies. Takara Bio USA, a subsidiary of Takara Bio Inc., published this study as the first in a new benchmarking series. This technology is now being further explored by top independent researchers, reflecting strong external validation beyond Takara Bio.

AACR poster presentation details

Title: Cross-platform comparison of spatial transcriptomics technologies in an FFPE lung squamous cell carcinoma sample
Abstract: View Source!/21436/presentation/10770
Session date and time: April 21, 2026, from 9:00 am–12:00 pm PST
Presenter: Bryan Bell, PhD
Location: Section 31
Poster board number: 17
Presentation number: 4960

(Press release, Takara Bio, APR 20, 2026, View Source [SID1234664576])

On April 20, 2026 Aditxt, Inc. (Nasdaq: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, reported that its precision oncology subsidiary, Ignite Proteomics, LLC ("Ignite" or "Ignite Proteomics"), has been featured in a peer-reviewed study published online ahead of print in npj Precision Oncology, a Nature journal. The study, led by investigators at Dana-Farber Cancer Institute, evaluated outcomes among patients with metastatic breast cancer treated with trastuzumab deruxtecan (T-DXd, marketed as Enhertu by AstraZeneca and Daiichi Sankyo) and assessed multiple quantitative HER2-related assays for their association with treatment outcomes.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

While conventional HER2 immunohistochemistry (IHC) showed some association with outcomes in the broader patient population, the study found that quantitative HER2-related assays provided more granular predictive information in several matched biomarker sub-cohorts. In those sub-cohorts, traditional IHC classification often showed limited predictive value compared with quantitative approaches. Ignite’s Reverse Phase Protein Array (RPPA) platform, the only commercially available multiplex assay in the study, was one of the quantitative methods that demonstrated meaningful predictive value for patient outcomes.

T-DXd is an approved treatment option for a broad population of patients with metastatic breast cancer, yet there is currently no reliable way to predict which patients will respond.

"According to several studies, approximately 40% of cancers do not respond to the FDA approved therapy at front line in a metastatic setting," said Jeff Busch, Chief Executive Officer of Ignite Proteomics. In oncology, published research and institutional analyses have shown that approved therapies often fail to benefit a substantial portion of the patients who receive them. A 2017 study published in the BMJ reported that 57% of cancer drug indications approved by the European Medicines Agency entered the market without evidence of improved survival or quality-of-life benefit. MIT researchers have noted that targeted tyrosine kinase inhibitors typically work for only 40% to 80% of patients expected to respond. Johns Hopkins has reported that only 15% to 20% of patients achieve durable results with immunotherapy.

Ignite’s RPPA platform measures multiple protein biomarkers, including pathway activation and payload-relevant markers, from a single tumor sample. In the Dana-Farber study, Ignite’s platform was the only commercially available multiplex assay evaluated and demonstrated predictive value in matched biomarker cohorts where conventional HER2 IHC showed limitations. Notably, the study found that TOPO1 expression, the target of T-DXd’s cytotoxic payload, was detectable by Ignite’s platform in certain HER2-negative patients, highlighting the potential value of measuring tumor biology beyond HER2 expression alone. Ignite’s assay is CLIA-certified, CAP-accredited, listed on the Medicare Clinical Laboratory Fee Schedule under AMA CPT code PLA 0249U, and orderable today on standard biopsy tissue.

"Cancer therapy has made extraordinary progress, but oncology still has a treatment-selection problem," added Busch. "Too many patients receive therapies without enough information about whether those therapies are likely to work for their tumor biology. That is not an indictment of the drugs. These are powerful therapies. The issue is that cancer is complex, and single-marker testing often does not capture the functional biology that drives response or resistance. Ignite’s RPPA platform was built to address that gap by measuring multiple proteins, pathway activation, and payload-relevant biology from the same tumor sample. In this study, one of the world’s leading breast cancer research teams evaluated our platform alongside standard testing, and our platform demonstrated predictive value where conventional testing had limitations. That is the opportunity: better data, better treatment selection, and fewer patients receiving therapies that were never likely to help them."

"This publication represents an important milestone for our subsidiary Ignite and reflects the strength of Aditxt’s model of advancing and scaling impactful health innovations," said Amro Albanna, Co-Founder and Chief Executive Officer of Aditxt. "Peer-reviewed clinical evidence from one of the world’s leading cancer research institutions is key to accelerating the commercialization of this platform and expanding access to it for millions of patients making treatment decisions without clear guidance on what will work. Our goal is to help ensure that more patients receive the right therapy at the right time, with the potential to improve outcomes and make a meaningful difference in people’s lives."

The full study is available open access at: View Source

(Press release, Dana-Farber Cancer Institute, APR 20, 2026, View Source [SID1234664575])

On April 20, 2026 Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company aiming to establish tomorrow’s standard of care to cure cancer and infectious diseases, reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the combination of its PKMYT1 inhibitor, lunresertib (Debio2513), and its WEE1 inhibitor, zedoresertib (Debio 0123).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The designation is for the treatment of adult patients with CCNE1 amplified, or a deleterious mutation in either FBXW7 or PPP2R1A, platinum-resistant/refractory ovarian cancer.

The FDA’s Fast Track program is designed to facilitate the development and expedite the review of new drugs intended to treat serious conditions and fill an unmet medical need. Programs granted Fast Track designation benefit from more frequent communication with the FDA and, if relevant criteria are met, may be eligible for Priority Review and Accelerated Approval of a New Drug Application (NDA).

Momentum Following AACR (Free AACR Whitepaper) Oral Presentation

This regulatory milestone follows the first clinical data disclosure from the MYTHIC Study (NCT04855656), a Phase I trial evaluating the lunresertib and zedoresertib combination in patients with advanced solid tumors harboring these specific genomic alterations. The data were featured yesterday in an oral presentation at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting by Dr. Timothy A. Yap, Medical Oncologist and Physician-Scientist at The University of Texas MD Anderson Cancer Center, and Principal Investigator of the MYTHIC study.

"The FDA’s decision to grant Fast Track designation for this combination therapy validates our synthetic lethality approach to treating high-unmet-need cancers," said Esteban Rodrigo Imedio, Executive Medical Director, Oncology, Debiopharm. "Coming immediately after Dr. Yap’s presentation of the MYTHIC data at AACR (Free AACR Whitepaper), this designation highlights the potential of combining lunresertib and zedoresertib to provide a meaningful new clinical option for patients with biomarker-selected ovarian cancer who have exhausted platinum-based therapies."

Addressing Unmet Need in Ovarian Cancer

Platinum-resistant or refractory ovarian cancer remains one of the most challenging malignancies to treat, with limited effective options for patients whose tumors have developed resistance. By targeting the DNA Damage Response (DDR) pathway through the dual inhibition of PKMYT1 and WEE1, the lunresertib/zedoresertib combination aims to exploit specific genomic vulnerabilities (CCNE1, FBXW7, or PPP2R1A) to induce tumor cell death.

ABOUT DNA DAMAGE REPAIR (DDR)

When cells have damaged DNA, they must undergo a repair process known as DDR to survive. Cancer cells rely heavily on DDR as they divide and grow uncontrollably. Inhibition of DDR, particularly in combination with other anticancer agents, prevents cancer cells from repairing their DNA, ultimately activating a programmed cell death process. DDR inhibitors such as zedoresertib (Debio 0123), Debiopharm’s WEE1 inhibitor, are currently being investigated in clinical and preclinical studies.

ABOUT PKMYT1 INHIBITION

Lunresertib (Debio2513) is a first-in-class, oral PKMYT1 inhibitor designed to exploit specific genetic vulnerabilities in solid tumors, such as CCNE1 amplification. By targeting PKMYT1, the drug induces synthetic lethality, preventing cancer cells from repairing DNA damage and forcing them into programmed cell death. As the most advanced PKMYT1 inhibitor in clinical development, lunresertib has shown encouraging proof-of-concept results both as monotherapy and in combination therapies within the ongoing MYTHIC trial.

(Press release, Debiopharm, APR 20, 2026, View Source [SID1234664574])

On April 20, 2026 Flatiron Health reported the publication of the Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework in the Journal of Clinical Oncology Clinical Cancer Informatics. The framework represents the first and most comprehensive, peer-reviewed approach to evaluating the quality and reliability of real-world data extracted by large language models (LLMs) and machine learning—setting a methodological benchmark for data integrity in oncology research.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As large language models emerge as a tool for clinical data extraction from sources such as electronic health records, the industry faces a tradeoff—AI can unlock speed and scale, but it requires rigorous validation. Flatiron’s VALID Framework makes real-world data quality transparent and measurable, enabling evidence that meets the bar for high-stakes clinical decisions. Specifically, the framework applies a rigorous, three-pillar approach: variable-level performance metrics that benchmark LLM extraction against expert human abstraction; automated verification checks that systematically identify logical inconsistencies and implausibilities in data; and replication and benchmark analyses that confirm LLM-extracted results replicate established clinical findings.

"By publishing this framework transparently, we hope to contribute to raising the bar across the industry," said Nathan Hubbard, Chief Executive Officer of Flatiron Health. "Our commitment to data quality while applying LLMs responsibly and rigorously has enabled us to work at scale—with longitudinal records across millions of patients and over 1.5 billion data points—without compromising the rigor that has defined Flatiron for decades."

Flatiron’s LLM-extracted data builds on the highest-quality, human-abstracted real-world oncology data. By combining AI with expert human abstraction, Flatiron delivers gold-standard data quality at scale without trading off the clinical rigor that makes it fit for use in the highest-stakes decisions in cancer care and drug development. Every LLM-enabled dataset is subject to the VALID Framework, alongside long term clinical and scientific oversight to ensure data that captures complete patient journeys and validated outcomes.

"The VALID Framework, combined with our robust clinical and methodological expertise, gives us—and our customers—a clear basis for evaluating whether efficiency and accuracy go hand in hand, as well as confidence in clinical and strategic decisions made using real-world data," said Jonathan Kish, PhD, MPH, Vice President and Head of Research Sciences at Flatiron Health. "We’re investing deeply in the underlying work: data models, multimodal depth, and resolving complex edge cases to ensure that we’re not just extracting more data; we’re extracting better data at scale, so every decision is informed by intelligence you can trust."

Read the full publication: Estevez M, Singh N, Dyson L, et al. Ensuring Reliability of Curated EHR-Derived Data: The Validation of Accuracy for LLM/ML-Extracted Information and Data (VALID) Framework. JCO Clin Cancer Inform. 2026. View Source

(Press release, Flatiron Health, APR 20, 2026, View Source [SID1234664572])

On April 20, 2026 Deck Bio, a biotechnology company advancing multi-pMHC targeted T cell engagers for solid tumors, reported new preclinical data for its lead program, DBXO-1, at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2026, which is being held April 17–22 in San Diego, California. The data were included in a poster titled "Preclinical characterization of DBXO-1, a multi-pMHC targeted bispecific T cell engager for major solid tumors."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The data highlight Deck Bio’s strategy to overcome key limitations of T cell engagers in solid tumors, including low antigen density, tumor heterogeneity, and the scarcity of tumor-specific surface targets. DBXO-1 is designed to recognize multiple cancer-associated peptide–major histocompatibility complexes (pMHCs) using a single engineered T cell receptor (TCR)-based binder. By combining a proprietary TCR stabilization technology (dbTv) with a sequence-agnostic specificity profiling platform (dbSCOPE), DBXO-1 enables precise targeting of intracellular cancer antigens in a novel T cell engager format (dbTCE).

"The data presented at AACR (Free AACR Whitepaper) showcase the rationale and structural foundation that enables multi-pMHC targeting," said Johanna Kaufmann, Ph.D., Chief Scientific Officer of Deck Bio. "Leveraging our dbSCOPE technology, we prioritize specificity as a core design principle for DBXO-1, ensuring highly potent multi-target activity does not come at the expense of off-target toxicity."

Key Preclinical Findings from AACR (Free AACR Whitepaper) 2026

Engineered TCR-based binders demonstrated multi-target engagement with ~1–2 nM affinity across target pMHCs.
The structural recognition mode of DBXO-1 binders enables multi-pMHC targeting.
Deep specificity profiling using dbSCOPE (Deck Bio’s Sequence-agnostic Comprehensive Off-target Profiling Engine) to interrogate binding against 13,849 HLA-A*02:01-presented peptides from healthy tissues showed minimal off-target interactions and a specificity profile comparable to an approved pMHC-TCE.
Functional assays under stringent conditions demonstrated a favorable potency window, with greater than 1,000-fold EC50 selectivity for target versus off-target peptides.
DBXO-1 dbTCEs mediated T cell activation and potent target-dependent cytotoxicity, with EC50s comparable to an established pMHC-TCE.
DBXO-1 dbTCEs showed no alloreactivity with closely related HLA alleles, consistent with a highly specific recognition profile.
DBXO-1 dbTCEs, which contain the stabilized dbTv moiety, demonstrated extended half-life in human FcRn transgenic mice, with an estimated elimination half-life exceeding 7.5 days.
"These data support our thesis that a multi-target approach can expand the reach of T cell engagers in solid tumors while maintaining a high bar for specificity," said Jack Silberstein, Ph.D., Founder and Chief Executive Officer of Deck Bio. "We are advancing DBXO-1 with a disciplined focus on safety, durability of response, and the potential to treat broader patient populations."

Deck Bio is continuing preclinical development of DBXO-1, including additional safety and efficacy studies. The company’s initial clinical development is expected to focus on biomarker-selected patient populations across major solid tumor indications, including non-small cell lung and gastroesophageal cancers, representing an estimated addressable patient population of approximately 120,000 biomarker-positive patients in the first-line metastatic setting across the U.S., Europe, the U.K., and Australia.

(Press release, Deck Bio, APR 20, 2026, View Source [SID1234664571])